Korea's Green Cross Files For Biobetter Of Shire's Hunter Syndrome Therapy Elaprase; Seeks Global Partners
This article was originally published in PharmAsia News
Executive Summary
SEOUL - South Korea's leading vaccine manufacturer Green Cross Corp. took a step forward in the biosimilars sector by submitting a marketing application to Korea FDA for a biobetter of Shire PLC's Elaprase (idursulfase) for Hunter syndrome. And now the company is looking for foreign partners
You may also be interested in...
Korea’s Green Cross Receives U.S. FDA Orphan Drug Status For Elaprase Biobetter
South Korea’s Green Cross wins U.S. FDA orphan drug designation for Hunterase, its biobetter of Shire’s Elaprase to treat Hunter syndrome.
Korean Health Ministry's New Pricing System Draws Industry Criticism
SEOUL - South Korea's Ministry of Health and Welfare held a two-day forum offering a rare opportunity for Korean and foreign pharmaceutical officials to offer comments on the ministry's controversial new pricing system
Green Cross Banking On Bioreactors To Develop Biosimilars, Biobetters Faster
SEOUL - Following a deal late last year to jointly develop biopharmaceutical products through disposable bioreactors, South Korea's vaccine giant Green Cross Corp. is expanding its collaboration to sell PBS Biotech, Inc.'s bioreactors to Korean companies